Scared off from the stock after Scorpion Capital released a scathing report last week, investors are warming back up to Ginkgo Bioworks (NYSE: DNA). As of 2:47 p.m. EDT, shares of Gingko Bioworks are up 15.2%. While there haven't been any analyst upgrades today that are motivating investors to propel the stock higher, yesterday saw Rahul Sarugaser, an analyst at Raymond James, initiate coverage on the stock with an outperform rating and a price target of $14.50, according to Thefly.com.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting